Mohammed Qintar1, J Aaron Grantham2, James Sapontis2, Kensey L Gosch2, William Lombardi2, Dimitri Karmpaliotis2, Jeffery Moses2, Adam C Salisbury2, David J Cohen2, John A Spertus2, Suzanne V Arnold2. 1. From the Department of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO (M.Q., J.A.G., K.L.G., A.C.S., D.J.C., J.A.S., S.V.A.); the Department of Cardiology, University of Missouri-Kansas City (M.Q., J.A.G., A.C.S., D.J.C., J.A.S., S.V.A.); the Department of Cardiology, Monash Cardiovascular Research Centre, MonashHeart, Monash Health and Department of Medicine (SCS at Monash), Monash University, Melbourne, Australia (J.S.); the Department of Cardiology, University of Washington, Seattle (W.L.); the Department of Cardiology, Columbia University, New York City, NY (D.K., J.M.). qintarm@umkc.edu. 2. From the Department of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO (M.Q., J.A.G., K.L.G., A.C.S., D.J.C., J.A.S., S.V.A.); the Department of Cardiology, University of Missouri-Kansas City (M.Q., J.A.G., A.C.S., D.J.C., J.A.S., S.V.A.); the Department of Cardiology, Monash Cardiovascular Research Centre, MonashHeart, Monash Health and Department of Medicine (SCS at Monash), Monash University, Melbourne, Australia (J.S.); the Department of Cardiology, University of Washington, Seattle (W.L.); the Department of Cardiology, Columbia University, New York City, NY (D.K., J.M.).
Abstract
BACKGROUND: Dyspnea is a common angina equivalent that adversely affects quality of life, but its prevalence in patients with chronic total occlusions (CTOs) and predictors of its improvement after CTO percutaneous coronary intervention (PCI) are unknown. We examined the prevalence of dyspnea and predictors of its improvement among patients selected for CTO PCI. METHODS AND RESULTS: In the OPEN CTO registry (Outcomes, Patient health status, and Efficiency iN Chronic Total Occlusion) of 12 US experienced centers, 987 patients undergoing CTO PCI (procedure success 82%) were assessed for dyspnea with the Rose Dyspnea Scale at baseline and 1 month after CTO PCI. Rose Dyspnea Scale scores range from 0 to 4 with higher scores indicating more dyspnea with common activities. A total of 800 (81%) reported some dyspnea at baseline with a mean (±SD) Rose Dyspnea Scale of 2.8±1.2. Dyspnea improvement was defined as a ≥1 point decrease in Rose Dyspnea Scale from baseline to 1 month. Predictors of dyspnea improvement were examined with a modified Poisson regression model. Patients with dyspnea were more likely to be female, obese, smokers, and to have more comorbidities and angina. Among patients with baseline dyspnea, 70% reported less dyspnea at 1 month after CTO PCI. Successful CTO PCI was associated with more frequent dyspnea improvement than failure, even after adjustment for other clinical variables. Anemia, depression, and lung disease were associated with less dyspnea improvement after PCI. CONCLUSIONS: Dyspnea is a common symptom among patients undergoing CTO PCI and improves significantly with successful PCI. Patients with other potentially noncardiac causes of dyspnea reported less dyspnea improvement after CTO PCI.
BACKGROUND:Dyspnea is a common angina equivalent that adversely affects quality of life, but its prevalence in patients with chronic total occlusions (CTOs) and predictors of its improvement after CTO percutaneous coronary intervention (PCI) are unknown. We examined the prevalence of dyspnea and predictors of its improvement among patients selected for CTO PCI. METHODS AND RESULTS: In the OPEN CTO registry (Outcomes, Patient health status, and Efficiency iN Chronic Total Occlusion) of 12 US experienced centers, 987 patients undergoing CTO PCI (procedure success 82%) were assessed for dyspnea with the Rose Dyspnea Scale at baseline and 1 month after CTO PCI. Rose Dyspnea Scale scores range from 0 to 4 with higher scores indicating more dyspnea with common activities. A total of 800 (81%) reported some dyspnea at baseline with a mean (±SD) Rose Dyspnea Scale of 2.8±1.2. Dyspnea improvement was defined as a ≥1 point decrease in Rose Dyspnea Scale from baseline to 1 month. Predictors of dyspnea improvement were examined with a modified Poisson regression model. Patients with dyspnea were more likely to be female, obese, smokers, and to have more comorbidities and angina. Among patients with baseline dyspnea, 70% reported less dyspnea at 1 month after CTO PCI. Successful CTO PCI was associated with more frequent dyspnea improvement than failure, even after adjustment for other clinical variables. Anemia, depression, and lung disease were associated with less dyspnea improvement after PCI. CONCLUSIONS:Dyspnea is a common symptom among patients undergoing CTO PCI and improves significantly with successful PCI. Patients with other potentially noncardiac causes of dyspnea reported less dyspnea improvement after CTO PCI.
Authors: David M Safley; J Aaron Grantham; Jason Hatch; Philip G Jones; John A Spertus Journal: Catheter Cardiovasc Interv Date: 2013-12-19 Impact factor: 2.692
Authors: Aiden Abidov; Alan Rozanski; Rory Hachamovitch; Sean W Hayes; Fatma Aboul-Enein; Ishac Cohen; John D Friedman; Guido Germano; Daniel S Berman Journal: N Engl J Med Date: 2005-11-03 Impact factor: 91.245
Authors: James Sapontis; Steven P Marso; David J Cohen; William Lombardi; Dimitri Karmpaliotis; Jeffrey Moses; William J Nicholson; Ashish Pershad; R Michael Wyman; Anthony Spaedy; Stephen Cook; Parag Doshi; Robert Federici; Craig R Thompson; Karen Nugent; Kensey Gosch; John A Spertus; J Aaron Grantham Journal: Coron Artery Dis Date: 2017-03 Impact factor: 1.439
Authors: Vasilis Babaliaros; Chandan Devireddy; Stamatios Lerakis; Robert Leonardi; Sebastian A Iturra; Kreton Mavromatis; Bradley G Leshnower; Robert A Guyton; Mihir Kanitkar; Patricia Keegan; Amy Simone; James P Stewart; Nima Ghasemzadeh; Peter Block; Vinod H Thourani Journal: JACC Cardiovasc Interv Date: 2014-07-30 Impact factor: 11.195
Authors: Suzanne V Arnold; David A Morrow; Yang Lei; David J Cohen; Elizabeth M Mahoney; Eugene Braunwald; Paul S Chan Journal: Circ Cardiovasc Qual Outcomes Date: 2009-06-02
Authors: Yevgeniy Khariton; Sophia Airhart; Adam C Salisbury; John A Spertus; Kensey L Gosch; J Aaron Grantham; Dimitrios Karmpaliotis; Jeffrey W Moses; William J Nicholson; David J Cohen; William Lombardi; James Sapontis; James M McCabe Journal: JACC Cardiovasc Interv Date: 2018-11-26 Impact factor: 11.195
Authors: Ali O Malik; Philip G Jones; Paul S Chan; Poghni A Peri-Okonny; Vittal Hejjaji; John A Spertus Journal: Circ Cardiovasc Qual Outcomes Date: 2019-04
Authors: Michael Wester; Franziska Koll; Mark Luedde; Christoph Langer; Markus Resch; Andreas Luchner; Karolina Müller; Florian Zeman; Michael Koller; Lars S Maier; Samuel Sossalla Journal: Clin Res Cardiol Date: 2022-09-13 Impact factor: 6.138
Authors: Ali O Malik; John A Spertus; James A Grantham; Poghni Peri-Okonny; Kensey Gosch; James Sapontis; Jeffrey Moses; William Lombardi; Dimitri Karmpaliotis; William J Nicholson; Firas Al Badarin; Adam C Salisbury Journal: Am J Cardiol Date: 2020-01-08 Impact factor: 2.778